Clinical Trials Browser

INDUSTRY × Multiple Myeloma × Prednisone × Clear all

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 2 FDA

Multiple Myeloma

NCT03217812 2024-04-25

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase 3 Completed

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Phase 2 Terminated

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT00689936 2019-11-20

FIRST

Phase 3 Completed

1,623 enrolled 56 charts

Multiple Myeloma

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT01335685 2018-01-23

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

61 enrolled 26 charts

Multiple Myeloma

NCT02072863 2017-05-02

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

Multiple Myeloma

NCT00799539 2015-12-02

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

No longer available

Multiple Myeloma

NCT02474563 2015-06-30

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Multiple Myeloma

NCT00911859 2014-11-18

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Phase 2 Completed

118 enrolled 16 charts

Multiple Myeloma

NCT00507416 2014-05-01

UPFRONT

Phase 3 Completed

502 enrolled 17 charts

Multiple Myeloma